AbbVie announced new research at the 2026 American Academy of Dermatology meeting highlighting the long-term efficacy and safety of risankizumab for psoriatic arthritis and psoriasis, and upadacitinib for atopic dermatitis, vitiligo, and alopecia areata. Key findings include sustained disease control, improved quality of life, and minimal disease activity in real-world settings. The data reinforce AbbVie's leadership in immune-mediated skin disease treatments and include FDA updates for risankizumab's use in genital and scalp psoriasis. Further Phase 3 trial results will be presented later this year.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
